Riyadh: The Saudi Food and Drug Authority (SFDA) has approved a clinical study to evaluate the safety and pharmacokinetics of an experimental mRNA-based therapy for treating propionic acidemia, a rare inherited disorder affecting amino acid metabolism.

According to Saudi Press Agency, the study is titled “A Global Phase 1/2 Open-Label Dose-Optimization Study to Evaluate the Safety and Pharmacokinetics of the Biologic Treatment (mRNA-3927) in Participants with Propionic Acidemia.” The research will investigate an innovative experimental therapy utilizing messenger RNA (mRNA) technology.

The goal of this therapy is to enable the body to produce the necessary enzyme internally, thereby restoring normal function, reducing the accumulation of toxic organic acids, and ultimately improving the patient’s metabolic balance.

The SFDA emphasized that this approval reflects its commitment to advancing clinical research and attracting scientific innovation, particularly in the field of rare diseases. This is supported by an efficient and transparent regulatory framework designed to expedite access to promising treatments.

This initiative also aligns with the objectives of the Health Sector Transformation Program, a key pillar of Saudi Vision 2030, which aims to establish the Kingdom as a leading regional hub for research, development, and health innovation.